11 completed. 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 11 |
Follow Fluzone®: new trials by email Literature Review of Fluzone® trials Research Report on Fluzone®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine - Influenza | Phase 2 | Completed | ModernaTX, Inc. | 172 | 2022-11-02 | 2025-11-24 |
| A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine VXA-A1.1, Fluzone®, Placebo Tablets - Influenza | Phase 2 | Completed | Vaxart | 179 | 2016-08-31 | 2022-10-06 |
| Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children Influenza virus vaccine, Vitamins A and D, Placebo - Healthy Participants | Phase 2 | Completed | St. Jude Children's Research Hospital | 87 | 2016-01-21 | 2019-10-29 |
| Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age FluLaval® Quadrivalent, Fluzone® - Influenza | Phase 2 | Completed | GlaxoSmithKline | 316 | 2013-10-23 | 2018-09-07 |
| A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age High-Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine - Influenza | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2010-11-01 | 2016-05-16 |
| A Study of Influenza Virus Vaccines in Children and Adults 2009-2010 Trivalent Influenza Virus Vaccine, 2008-2009 Trivalent Influenza Virus Vaccine, Quadrivalent Influenza Virus Vaccine - Influenza | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 600 | 2009-10-01 | 2013-12-12 |
| Influenza Vaccine in Pregnant Women Fluzone®, Fluarix® - Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 102 | 2009-06-01 | 2012-06-13 |
| Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults Fluzone: Influenza virus vaccine - Influenza | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 110 | 2008-01-01 | 2016-04-14 |
| Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose) - Influenza, Myxovirus Infection | Phase 2 | Completed | Sanofi | 2098 | 2007-10-01 | 2016-05-16 |
| Trial to Describe the Safety and Immunogenicity of Fluzone® Inactivated, Split-Virion Influenza Virus - Influenza | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 124 | 2007-08-01 | 2016-04-14 |
| Immunogenicity and Safety of Different Doses of Fluzone® Influenza Fluzone® (IM), Fluzone® - Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 217 | 2005-11-01 | 2013-06-03 |
Influenza, Human (11)
Sanofi Pasteur, a Sanofi Company (4) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · GlaxoSmithKline (1) · ModernaTX, Inc. (1) · Sanofi (1) · St. Jude Children's Research Hospital (1) · Vaxart (1)
United States (11)
Nehali Patel, MD (1) · Sean Tucker, PhD (1)